SCHEMBL4152071

SCHEMBL4152071

CC(C)CCC(C)NC(=O)c1ccnc2[nH]c(-c3ccc(NCCN(C)C)cc3)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.41
UHRF1 Q96T88 1/20 0.41
ERCC1 P07992 1/20 0.38
FEN1 P39748 1/20 0.38
ERCC4 Q92889 1/20 0.38
GSK3B P49841 4/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PARP1 P09874 3/20 0.34
CLK2 P49760 2/20 0.33
CLK3 P49761 2/20 0.33
DYRK1A Q13627 2/20 0.33
HDAC4 P56524 1/20 0.33
LTA4H P09960 1/20 0.33
CDC7 O00311 1/20 0.33
CDK19 Q9BWU1 1/20 0.33
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4161286 0.93 RAD52 (0.42) RAD52UHRF1ERCC1FEN1ERCC4
SCHEMBL4157347 0.89 RAD52 (0.41) RAD52UHRF1ERCC1FEN1ERCC4
SCHEMBL4160387 0.86 RAD52 (0.43) RAD52UHRF1GSK3BNPC1RAB9A
SCHEMBL8234676 0.86 NPC1 (0.34) ERCC1FEN1ERCC4GSK3BNPC1
SCHEMBL4148192 0.85 GSK3B (0.43) GSK3BNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4961738 0.83 RAD52 (0.43) RAD52UHRF1GSK3BNPC1RAB9A
SCHEMBL4152290 0.82 RAD52 (0.44) RAD52UHRF1GSK3BNPC1RAB9A
SCHEMBL4144903 0.81 RAD52 (0.46) RAD52UHRF1GSK3BNPC1RAB9A
SCHEMBL4161480 0.80 HDAC4 (0.43) RAD52UHRF1GSK3BALDH1A1PARP1
SCHEMBL4147748 0.80 RAD52 (0.42) RAD52UHRF1GSK3BNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 RAD52 4618/4885UHRF1 3834/4885ERCC1 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.